Insider trades › Srinivas Akkaraju
Srinivas Akkaraju
A corporate insider: an officer, director or owner of more than 10% of a company. Insiders report their trades to the SEC on Form 4The form insiders use to report each purchase or sale of their company's stock. It is due within two business days of the trade. · Last filing Oct 27, 2026
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, list Srinivas Akkaraju's open-market buys and sells across companies in the last two years, with the Form 4 links.
Using 13F.ai, how did the stocks Srinivas Akkaraju bought perform after the purchase compared with the S&P 500?
Using 13F.ai, are other insiders at the same companies buying or selling at the same time as Srinivas Akkaraju?
Connect your AI · Plans and the 7-day free trial (card required)
Buying and selling by quarter
Dollars bought and sold on the open market over the last two years.
Bought Sold
By trade date, using the shares and price reported for each trade. Stock grants, option exercises and shares withheld for tax are left out.
Roles
The companies where this person reports as an insider, and their position at each, most recent first.
| SRRK Scholar Rock Holding Corporation | Director | Oct 27, 2026 |
| ALMS Alumis Inc. | Director | Sep 9, 2026 |
| VTVT vTv Therapeutics Inc. | Director, 10% owner | Jun 29, 2026 |
| KLRS Kalaris Therapeutics, Inc. | Director, 10% owner | Jun 4, 2026 |
| MLYS Mineralys Therapeutics, Inc. | Director, 10% owner | Feb 20, 2026 |
| NGNE Neurogene Inc. | 10% owner | Nov 27, 2024 |
Roles come from the filings themselves and can change over time.
Latest open-market trades
Purchases and sales at every company, most recent filing first.
| How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss. | Filing | ||||||
|---|---|---|---|---|---|---|---|
| Oct 26, 2026 | SRRK Scholar Rock Holding Corporation | Buy | 48,988 | $41.59 | $2.0M | +5.0% | Form 4 ↗ |
| Oct 26, 2026 | SRRK Scholar Rock Holding Corporation | Buy | 97,982 | $41.59 | $4.1M | +5.0% | Form 4 ↗ |
| Oct 23, 2026 | SRRK Scholar Rock Holding Corporation | Buy | 94,000 | $41.31 | $3.9M | +4.9% | Form 4 ↗ |
| Oct 23, 2026 | SRRK Scholar Rock Holding Corporation | Buy | 500 | $41.82 | $20.9K | +4.9% | Form 4 ↗ |
| Oct 23, 2026 | SRRK Scholar Rock Holding Corporation | Buy | 47,000 | $41.31 | $1.9M | +4.9% | Form 4 ↗ |
| Oct 23, 2026 | SRRK Scholar Rock Holding Corporation | Buy | 1,000 | $41.82 | $41.8K | +4.9% | Form 4 ↗ |
| Sep 8, 2026 | ALMS Alumis Inc. | Sale | 48,066 | $10.55 | $507.1K | -45.6% | Form 4 ↗ |
| Sep 8, 2026 | ALMS Alumis Inc. | Sale | 48,065 | $10.55 | $507.1K | -45.6% | Form 4 ↗ |
| Sep 8, 2026 | ALMS Alumis Inc. | Buy | 273,291 | $10.63 | $2.9M | -45.6% | Form 4 ↗ |
| Sep 8, 2026 | ALMS Alumis Inc. | Buy | 273,290 | $10.63 | $2.9M | -45.6% | Form 4 ↗ |
| Sep 4, 2026 | ALMS Alumis Inc. | Buy | 220,070 | $11.17 | $2.5M | -47.5% | Form 4 ↗ |
| Sep 4, 2026 | ALMS Alumis Inc. | Buy | 220,070 | $11.17 | $2.5M | -47.5% | Form 4 ↗ |
| Jan 9, 2026 | ALMS Alumis Inc. | Buy | 588,235 | $17.00 | $10.0M | -80.1% | Form 4 ↗ |
| Oct 7, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 12,400 | $40.18 | $498.2K | -3.4% | Form 4 ↗ |
| Oct 7, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 4,403 | $40.97 | $180.4K | -3.4% | Form 4 ↗ |
| Oct 7, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 12,796 | $39.31 | $503.0K | -3.4% | Form 4 ↗ |
| Dec 5, 2025 | ALMS Alumis Inc. | Buy | 51,380 | $10.73 | $551.3K | -59.7% | Form 4 ↗ |
| Dec 5, 2025 | ALMS Alumis Inc. | Buy | 64,969 | $8.95 | $581.5K | -59.7% | Form 4 ↗ |
| Dec 5, 2025 | ALMS Alumis Inc. | Buy | 70,028 | $10.01 | $701.0K | -59.7% | Form 4 ↗ |
| Dec 4, 2025 | ALMS Alumis Inc. | Buy | 66,027 | $8.18 | $540.1K | -42.8% | Form 4 ↗ |
| Dec 3, 2025 | ALMS Alumis Inc. | Buy | 100,000 | $7.75 | $775.0K | -38.9% | Form 4 ↗ |
| Dec 2, 2025 | ALMS Alumis Inc. | Buy | 96,000 | $7.55 | $724.8K | -35.1% | Form 4 ↗ |
| Dec 1, 2025 | ALMS Alumis Inc. | Buy | 86,350 | $7.46 | $644.2K | -34.7% | Form 4 ↗ |
| Nov 28, 2025 | ALMS Alumis Inc. | Buy | 38,702 | $7.64 | $295.7K | -37.4% | Form 4 ↗ |
| Nov 26, 2025 | ALMS Alumis Inc. | Buy | 48,537 | $7.64 | $370.8K | -37.7% | Form 4 ↗ |
| Nov 20, 2025 | ALMS Alumis Inc. | Buy | 125,743 | $7.20 | $905.3K | -34.7% | Form 4 ↗ |
| Nov 19, 2025 | ALMS Alumis Inc. | Buy | 137,772 | $6.56 | $903.8K | -28.6% | Form 4 ↗ |
| Nov 18, 2025 | ALMS Alumis Inc. | Buy | 102,652 | $6.05 | $621.0K | -26.9% | Form 4 ↗ |
| Nov 17, 2025 | ALMS Alumis Inc. | Buy | 914 | $5.51 | $5,036 | -12.9% | Form 4 ↗ |
| Nov 13, 2025 | ALMS Alumis Inc. | Buy | 276,179 | $5.25 | $1.4M | -6.2% | Form 4 ↗ |
| Oct 6, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 13,748 | $39.52 | $543.3K | -3.8% | Form 4 ↗ |
| Oct 6, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 18,414 | $37.89 | $697.7K | -3.8% | Form 4 ↗ |
| Oct 6, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 80,863 | $38.68 | $3.1M | -3.8% | Form 4 ↗ |
| Oct 3, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 11,011 | $35.61 | $392.1K | +2.6% | Form 4 ↗ |
| Oct 3, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 56,703 | $36.74 | $2.1M | +2.6% | Form 4 ↗ |
| Oct 3, 2025 | SRRK Scholar Rock Holding Corporation | Buy | 319,700 | $37.42 | $12.0M | +2.6% | Form 4 ↗ |
| Sep 4, 2025 | MLYS Mineralys Therapeutics, Inc. | Buy | 588,235 | $25.50 | $15.0M | -69.9% | Form 4 ↗ |
| May 5, 2025 | ALMS Alumis Inc. | Buy | 138,368 | $4.58 | $633.7K | -6.6% | Form 4 ↗ |
| May 5, 2025 | ALMS Alumis Inc. | Buy | 22,002 | $5.27 | $116.0K | -6.6% | Form 4 ↗ |
| May 2, 2025 | ALMS Alumis Inc. | Buy | 159,920 | $4.55 | $727.6K | -11.1% | Form 4 ↗ |
| Mar 13, 2025 | MLYS Mineralys Therapeutics, Inc. | Buy | 600,000 | $13.50 | $8.1M | -23.2% | Form 4 ↗ |
| Nov 26, 2024 | NGNE Neurogene Inc. | Buy | 10,803 | $26.01 | $281.0K | -36.5% | Form 4 ↗ |
| Nov 26, 2024 | NGNE Neurogene Inc. | Buy | 20,748 | $24.91 | $516.8K | -36.5% | Form 4 ↗ |
| Nov 26, 2024 | NGNE Neurogene Inc. | Buy | 15,219 | $26.73 | $406.8K | -36.5% | Form 4 ↗ |
| Nov 26, 2024 | NGNE Neurogene Inc. | Buy | 2,000 | $27.50 | $55.0K | -36.5% | Form 4 ↗ |
| Oct 7, 2024 | SRRK Scholar Rock Holding Corporation | Sale | 510,000 | $27.50 | $14.0M | -6.8% | Form 4 ↗ |
| Oct 7, 2024 | SRRK Scholar Rock Holding Corporation | Sale | 510,000 | $30.00 | $15.3M | -6.8% | Form 4 ↗ |
| Oct 7, 2024 | SRRK Scholar Rock Holding Corporation | Sale | 155,713 | $32.50 | $5.1M | -6.8% | Form 4 ↗ |
Each row links to its Form 4. Since trade compares the stock’s move from the close on the trade date (or the next trading day) to its latest close with the S&P 500 over the same days, adjusted for splits and excluding dividends. It describes the stock, not what the trader made: we don’t know their purchase price, position size or later sales. A dash means the trade isn’t matched to a listed stock, or there is no closing price after it yet.
When several people report on the same filing, we list it under the first one named, so trades by someone usually listed second may be missing here. Information, not investment advice: see the disclaimer.